Please use this identifier to cite or link to this item:
Title: Tumour eradication with high-dose idarubicin-anti-Ly-2.1 with murine tumour necrosis factor-alpha in mice.
Austin Authors: Pietersz, Geoffrey A;Bogdanovski, M;Li, W
Affiliation: Austin Research Institute, Austin Hospital, Heidelberg, Victoria, Australia
Issue Date: 1-Jun-1997
Publication information: Immunology and Cell Biology; 75(3): 253-8
Abstract: The antitumour efficacy of Ida-anti-Ly-2.1 immunoconjugate in combination with murine TNF-alpha (mTNF-alpha) has been evaluated in a disseminated murine thymic lymphoma model E3. This tumour model shows characteristics similar to lymphoma in humans with widely disseminated tumour in major organs. In vitro both idarubicin (Ida) and Ida-anti-Ly-2.1 showed additive and synergistic cytotoxic effects, respectively, with mTNF-alpha when tested using the isobolagram method. Similar synergistic effects were also seen in vivo. Tumour-bearing mice were treated with various doses of mTNF-alpha and Ida alone, however, neither showed a therapeutic response in mice. When mice were treated with Ida-anti-Ly-2.1 'early' the median survival time (MST) was increased by 8 days, however, 'late' treatment was ineffective. Combination therapy of mTNF-alpha and Ida-anti-Ly-2.1 conjugate (42 micrograms) given 'early' was capable of curing 50% of mice. However, when tumour-bearing mice were given a high dose (234 micrograms) of Ida-anti-Ly-2.1 together with mTNF-alpha 100% of mice survived disease free. Such an effect was not observed when free mTNF-alpha, Ida-anti-Ly-2.1, anti-Ly-2.1 or a mixture of anti-Ly-2.1+mTNF-alpha was given at the same dose. These results show that a combination of very toxic drug immunoconjugates and TNF could lead to the eradication of disseminated tumour in mice and may be relevant for the treatment of minimal residual disease in cancer patients.
Gov't Doc #: 9243290
DOI: 10.1038/icb.1997.39
Journal: Immunology and cell biology
Type: Journal Article
Subjects: Animals
Antibiotics, Antineoplastic.administration & dosage
Antibodies, Monoclonal.administration & dosage
Antigens, Ly
Drug Synergism
Idarubicin.administration & dosage
Immunoconjugates.administration & dosage
Mice, Inbred BALB C
Mice, Inbred C57BL
Thymus Neoplasms.therapy
Tumor Cells, Cultured
Tumor Necrosis Factor-alpha.administration & dosage
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jul 19, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.